Nymox reports positive results from benign prostatic hyperplasia study

In all available and eligible patients assessed at 12 months post-treatment, more than seven times as many positive responses to treatment were documented in patients who received the NX-1207 therapeutic dose as compared to patients who received the comparator finasteride, an approved drug for benign prostatic hyperplasia (BPH).

In the study, positive response was defined as a nine point or more BPH symptom score improvement without any subsequent BPH treatments of any kind, and corresponded to a minimum 37.5% improvement in BPH symptoms.

The difference in response rate between NX-1207 and the comparator was statistically significant (p=0.01). The range of improvement in individual patients who received NX-1207 and were categorized as responders was 37.5 to 93% reduction in symptoms. Overall, 76.7% of subjects who received a single dose of NX-1207 reported no further BPH treatment after 12 months (p=0.01).

In the initial study, mean improvement in the NX-1207 intent-to-treat group at 90 days was 9.71 points (p=0.001). This treatment benefit compares favorably to the mean symptom score improvement typically found after three months for currently approved BPH medications such as alpha blockers and five alpha reductase inhibitors. Patients treated with NX-1207 did not report any of the sexual side effects or the low blood pressure side effects associated with the approved drugs, the company said.

NX-1207 is a novel drug developed by Nymox which is in Phase III development for the treatment of BPH.